A medical oncologist discusses the referral process for patients being considered for CAR T-cell therapy in early relapsed/refractory multiple myeloma, highlighting factors that inform treatment selection.
Case: A 70-Year-Old Man with Early Relapse Multiple Myeloma
Clinical Presentation:
Prior Treatments:
Follow up and Clinical Workup at Relapse:
Grajales-Cruz Interprets Data for Earlier- Line CAR T-Cell Therapy in R/R MM
June 8th 2024During a Case-Based Roundtable® event, Ariel F. Grajales-Cruz, MD, discussed data from the KarMMa-3 trial of idecabtagene vicleucel and real-world data on the CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.
Read More